We examined the pharmacokinetic properties of vancomycin conjugated to a bone-targeting agent (BT) with high affinity for hydroxyapatite after systemic intravenous administration. The results confirm enhanced persistence of BT-vancomycin in plasma and enhanced accumulation in bone relative to vancomycin. This suggests that BT-vancomycin may be a potential carrier for the systemic targeted delivery of vancomycin in the treatment of bone infections, potentially reducing the reliance on surgical debridement to achieve the desired therapeutic outcome.

Document Type


Publication Date


Notes/Citation Information

Published in Antimicrobial Agents and Chemotherapy, v. 60, no. 3, p. 1865-1868.

Copyright © 2016, American Society for Microbiology. All Rights Reserved.

The copyright holders have granted the permission for posting the article here.

Digital Object Identifier (DOI)


Funding Information

This study was supported by funding from Pradama, Inc., to W.M.P. and a Department of Defense Peer-Reviewed Orthopaedic Research Program Expansion Award (W81XWH-15-1-0716) to M.S.S. and P.A.C.